Drug Restores Hair in Some With Alopecia: FAQ

From the WebMD Archives

Aug. 19, 2014-- A drug used to treat a rare bone marrow cancer caused hair to grow back in some people with alopecia areata, an autoimmune disease that attacks the hair follicles, scientists have found.

A small study shows that the drug, ruxolitinib, was effective in mice and in three people with the disease. Alopecia areata is thought to affect between 4 million and 5 million Americans, can strike at any age, and affects men and women equally. They are generally otherwise healthy. But they lose patches of hair and, in rare cases, all of their body hair.

This is the second report this summer about a drug causing hair to regrow in someone with alopecia. In June, the Journal of Investigative Dermatology published a report online from Yale University researchers regarding a man with almost no hair on his body. He grew a full head of hair, including eyebrows and eyelashes, after taking the drug tofacitinib for 8 months. Tofacitinib was approved in 2012 for the treatment of rheumatoid arthritis and belongs to the same class of drugs as ruxolitinib.

The two scientists who led the new study are Raphael Clynes, MD, PhD, who recently left Columbia University Medical Center to work for Bristol-Myers Squibb, and Angela Christiano, PhD, a professor in the departments of dermatology and of genetics and development at Columbia. Here, they discuss their research, which appears online in Nature Medicine.

Q. Why would you think to use a cancer drug to treat alopecia?

A. Christiano's past research suggested that in people with alopecia, hair follicles send out a false "danger signal" that triggers the immune system to attack them. Further research, which she and Clynes describe in their new report, identifies one way to stop the attack: a new class of drugs known as JAK inhibitors. Ruxolitinib, approved in 2011 to treat the bone marrow cancer myelofibrosis, is one such drug, along with tofacitinib, which Christiano and Clynes found to be effective in treating mice with alopecia.

Q. How many people with alopecia have been treated with ruxolitinib?

Continued

A. Clynes and Christiano have treated a total of a dozen, the first three of whom are included in the new study. After 5 months of treatment, all three regrew more than half of the hair they had lost.

“They were very pleased and happy,” Clynes says. Of the next six patients, though, only three regrew that much hair, he says. The last three haven’t been treated long enough to reach any conclusions.

Q. If ruxolitinib and tofacitinib promote hair growth in people with alopecia, could they be used to treat run-of-the mill male-pattern baldness?

A. “It’s not obvious at this point,” Christiano says. She's looking into that question, though.

Q. What are the side effects?

A. The labeling for the drug lists a number of serious potential side effects, such as low blood counts and infection. More common and less serious side effects include headache and dizziness, according to the labeling. Clynes says one person in his study has had “a touch of anemia. Nothing significant.”

Because people with alopecia are generally healthy, he says, “we didn’t expect much change in the blood counts.” The side effects may be worse in people with underlying and chronic illnesses, he says. And ruxolitinib probably does suppress the immune system, putting people at risk for infections.

Q. Why would anyone take a potentially risky medication for months just to regrow hair?

A. “This is a group of patients who’ve really had nothing,” says Christiano, who was diagnosed with alopecia at age 30 in 1996. “There’s no FDA-approved treatment. They’re desperate for something that works.”

Christiano, who’d lost 20% to 25% of her hair when she was diagnosed, tried steroid injections into the affected areas, a common treatment. “Some people spontaneously recover with no treatment,” she says, while in others the disease progresses to the point that they don’t have hair anywhere on their body, a condition called alopecia universalis. As a result of some publicity about her study, she says, her inbox has been flooded with emails from people eager to test ruxolitinib or other drugs in its class for alopecia.

Continued

Q. When the people in the study stopped taking ruxolitinib, did their hair fall out again?

A. Scientists are continuing to check their hair growth every couple of months. It’s plausible that the drug could have a permanent effect, Clynes says. On the other hand, the drug might have only put the disease into remission, so it could eventually come back and cause hair loss.

Q. Wouldn’t it make more sense to rub the drug on the skin where you’d like to grow hair, rather than swallowing it in a pill?

A. “It would be wonderful to have both an oral and a topical” version of a drug that could cause hair to regrow in alopecia patients, Clynes says. But no topical form of ruxolitinib or tofacitinib has been approved for human use, so he and Christiano mixed up their own with ingredients from China and tested them on the mice, with excellent results.

Q. Since ruxolitinib is already on the market to treat that bone marrow cancer, couldn’t people with alopecia ask their doctor for a prescription?

A. Once the FDA approves a drug to treat one condition, doctors are free to prescribe for others, a practice called “off-label” use. But insurers generally cover medications only for their approved uses.

Jakafi, the brand name for ruxolitinib, costs $8,753 for a month’s supply, which amounts to more than $100,000 a year, says Pamela Murphy. She's vice president for investor relations and corporate communications at Incyte, the Wilmington, DE, company that markets the drug.

“I think that is a pretty high price point,” Clynes says. “Our hope is a year of therapy wouldn’t be required.” If a wealthy person with alopecia wanted to try the drug, he says, “I would not personally be uncomfortable prescribing the medicine if the patient was otherwise healthy and young and had an expected low-level risk of complications.”

Q. What’s the next step?

A. Clynes and Christiano are seeking funding to conduct a randomized trial comparing a JAK inhibitor -- besides ruxolitinib and tofacitinib -- with an inactive pill in people with alopecia.

Continued

In a partnership with drug companies Novartis and Eli Lilly, Incyte does not have any rights to develop Jakafi tablets for any use other than treating cancer, so it won’t ever get approved to treat alopecia, Murphy says. “We don’t want to raise expectations of patients inappropriately,” she says.

But, she says, Incyte can do what it likes with the topical form of the drug. While the company has tested the topical form on people with psoriasis (a long-term skin disorder that, like alopecia, is an autoimmune disease), it has no plans to pursue the topical form for that purpose.

“Right now we’re not doing anything with the topical, but we’re interested in working with Columbia [University Medical Center],” she says.

WebMD Health News Reviewed by Michael W. Smith, MD on August 19, 2014

Sources

SOURCES: 

Raphael Clynes, MD, PhD, Bristol-Myers Squibb. 

Angela Christiano, PhD, professor, department of dermatology, department of genetics and development, Columbia University Medical Center. 

Pamela Murphy, vice president for investor relations and corporate communications, Incyte. 

Xing, L. Nature Medicine, published online Aug. 17, 2014.

News release, Yale University.

© 2014 WebMD, LLC. All rights reserved.

Pagination